Compare FTLF & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | KPTI |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.6M | 148.0M |
| IPO Year | N/A | 2013 |
| Metric | FTLF | KPTI |
|---|---|---|
| Price | $15.83 | $7.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $23.00 | $22.17 |
| AVG Volume (30 Days) | 17.2K | ★ 452.5K |
| Earning Date | 11-13-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | $70,561,000.00 | ★ $142,530,000.00 |
| Revenue This Year | $32.74 | $3.82 |
| Revenue Next Year | $50.36 | N/A |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $9.83 | $3.51 |
| 52 Week High | $20.98 | $10.75 |
| Indicator | FTLF | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 50.78 |
| Support Level | $15.01 | $6.36 |
| Resistance Level | $16.90 | $7.09 |
| Average True Range (ATR) | 0.51 | 0.69 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 49.21 | 35.77 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.